A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapiesJournal of Cranio-Maxillofacial Surgery
Date of this Version3-1-2013
Document TypeJournal Article
AbstractThe transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control.
Citation InformationPatrick H. Warnke, Andreas Humpe, Dirk Strunk, Sebastien Stephens, et al.. "A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies" Journal of Cranio-Maxillofacial Surgery Vol. 41 Iss. 2 (2013) p. 153 - 161 ISSN: 1010-5182
Available at: http://works.bepress.com/qin_liu/25/